18 September 2018: Schizophrenia is a mental disorder characterized by hallucinations, delusions, and several other cognitive difficulties. It commonly occurs between the ages 16 and 30 years and usually has a slow onslaught. Hence, in most cases, it remains undiagnosed for several years. However, in some exceptional cases it can also occur suddenly and develop rapidly. Common symptoms of schizophrenia include cognitive difficulties, hallucinations, and poor concentration among others. However, they may vary from one individual to another. Chemical imbalance in brain, environmental factors, genetic inheritance, and other such are the major causes. The types of common schizophrenia drugs include first-generation, second-generation, and third-generation antipsychotics.
Second- and Third-gen Antipsychotics: Most Common & Widely Prescribed Drugs
At present, second- and third-generation antipsychotic drugs are the standard medicines used in the treatment of schizophrenia. Second-generation drugs hold a prominent share in terms of demand, mainly due to their faster and positive results. Third-generation drugs, which include aripiprazole, are also expected to witness maximum demand in the forthcoming years. This growth can be attributed to tolerability and clinical safety offered by them. Many healthcare organizations support and focus on Research and Development (R&D) activities to find better treatment options for the disease.
For example, a research supported by the National Institute of Health (NIH) is currently developing a new line of antipsychotic drugs for the treatment of schizophrenia, bipolar disorder, and other similar disorders. With the discovery of a commonly prescribed drug may help treat these disorders in a more effective manner. Researchers believe that this discovery will open avenues for the design of a whole new generation of antipsychotics with fewer adverse effects and more positive effects.
Market Insights
A report published by Grand View Research, Inc. suggests that the global schizophrenia drugs market would reach at $ 7.9 billion by 2022 growing at a healthy CAGR of 2.5 % over the forecast period (from 2017 to 2022). The key factors behind this growth include rising number of schizophrenia patients, enhanced drug delivery technologies, and availability of Long-acting Injectable (LAIs). Moreover, rising number of physicians in the field of mental health along with increasing awareness among people regarding available treatments is also likely to fuel the market growth in coming years.
In-Depth Research Report On Schizophrenia Drugs Market:
https://www.grandviewresearch.com/industry-analysis/schizophrenia-drugs-market
No comments:
Post a Comment